잠시만 기다려 주세요. 로딩중입니다.

Hepatic Hippo signaling inhibits development of hepatocellular carcinoma

Clinical and Molecular Hepatology 2020년 26권 4호 p.742 ~ 750
Liu Yuchen, Wang Xiaohui, Yang Yingzi,
소속 상세정보
 ( Liu Yuchen ) - Harvard School of Dental Medicine Department of Developmental Biology
 ( Wang Xiaohui ) - Harvard School of Dental Medicine Department of Developmental Biology
 ( Yang Yingzi ) - Harvard School of Dental Medicine Department of Developmental Biology

Abstract


Primary liver cancer is one of the most common cancer worldwide. Hepatocellular carcinoma (HCC) in particular, is the second leading cause of cancer deaths in the world. The Hippo signaling pathway has emerged as a major oncosuppressive pathway that plays critical roles inhibiting hepatocyte proliferation, survival, and HCC formation. A key component of the Hippo pathway is the inhibition of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) transcription factors by the Hippo kinase cascade. Aberrant activation of YAP or TAZ has been found in several human cancers including HCC. It is also well established that YAP/TAZ activation in hepatocytes causes HCC in mouse models, indicating that YAP/TAZ are potential therapeutic targets for human liver cancer. In this review, we summarize the recent findings regarding the multifarious roles of Hippo/YAP/TAZ in HCC development, and focus on their cell autonomous roles in controlling hepatocyte proliferation, differentiation, survival and metabolism as well as their non-cell autonomous in shaping the tumor microenvironment.

키워드

Hippo; YAP/TAZ; Hepatocytes; Liver; Carcinoma, Hepatocellular

원문 및 링크아웃 정보

등재저널 정보